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Abstract
 
Immune and inflammatory systems are controlled by multiple cytokines, including interleukins
(ILs) and interferons. These cytokines exert their biological functions through Janus tyrosine
kinases and signal transducer and activator of transcription (STAT) transcription factors. We re-
cently identified two intrinsic Janus kinase (JAK) inhibitors, JAK binding protein (JAB; also re-
ferred to as suppressor of cytokine signaling [SOCS1]/STAT-induced STAT inhibitor [SSI1])
and cytokine-inducible SH2 protein (CIS)3 (or SOCS3/SSI3), which play an essential role in
the negative regulation of cytokine signaling. We have investigated the role of STATs and
these JAK inhibitors in intestinal inflammation. Among STAT family members, STAT3 was
most strongly tyrosine phosphorylated in human ulcerative colitis and Crohn’s disease patients
as well as in dextran sulfate sodium (DSS)-induced colitis in mice. Development of colitis as
well as STAT3 activation was significantly reduced in IL-6–deficient mice treated with DSS,
suggesting that STAT3 plays an important role in the perpetuation of colitis. CIS3, but not
JAB, was highly expressed in the colon of DSS-treated mice as well as several T cell–dependent
colitis models. To define the physiological role of CIS3 induction in colitis, we developed a
JAB mutant (F59D-JAB) that overcame the inhibitory effect of both JAB and CIS3 and created
transgenic mice. DSS induced stronger STAT3 activation and more severe colitis in F59D-JAB
transgenic mice than in their wild-type littermates. These data suggest that hyperactivation of
STAT3 results in severe colitis and that CIS3 plays a negative regulatory role in intestinal in-
flammation by downregulating STAT3 activity.
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Introduction
 
Proinflammatory cytokines have been demonstrated to play
a crucial role in the pathogenesis of inflammatory bowel
 
diseases including Crohn’s disease (CD).
 
1
 
 It has been shown
 
that in addition to IFN-
 
g
 
, IL-6 is one of the main cytokines
secreted by lamina propria cells, and that CD patients pro-
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Abbreviations used in this paper:
 
 CD, Crohn’s disease; CIS, cytokine-
inducible SH2 protein; DIG, digoxigenin; DSS, dextran sulfate sodium;
IBD, inflammatory bowel disease; IC, infectious colitis; JAK, Janus ki-
nase; LIF, leukemia inhibitory factor; RT, reverse transcription; STAT,
signal transducer and activator of transcription; Tg, transgenic; UC, ulcer-
ative colitis; WT, wild-type. 
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duce substantially higher amounts of IL-6 than control pa-
tients (1–4). Strong expression of IL-6 has also been re-
ported in acute bowel inflammation induced by dextran
sulfate sodium (DSS) in mice (5). A recent study using anti–
IL-6 receptor antibodies demonstrated that IL-6 plays a
critical role in the development of Th1 cell–mediated
chronic colitis (6, 7). IL-6 also plays a central role in arthri-
tis, which is confirmed by recent reports of IL-6 gene–dis-
rupted mice that were shown to be resistant to antigen-
induced arthritis (8, 9) and collagen-induced arthritis (10).
IL-6 and its related cytokines, including leukemia inhibi-
tory factor (LIF), oncostatin M (OSM), and IL-11, prefer-
entially activate Janus kinase (JAK) tyrosine kinases and the
signal transducer and activator of transcription (STAT)3
transcription factor. Furthermore, antiinflammatory cyto-
kine IL-10 mainly utilizes STAT3 (11). Therefore, the reg-
ulatory mechanism of the JAK-STAT3 pathway is ex-
tremely important for the understanding of inflammation.
We have reported a new family of cytokine-inducible
SH2 proteins (CIS) that are involved in the negative regu-
lation of cytokine signals, especially JAKs and STATs (for a
review, see reference 12). The first identified CIS gene,
CIS1, has been shown to be a negative feedback regulator
of the STAT5 pathway (13, 14). We recently cloned other
CIS family members, JAK binding protein (JAB) and CIS3,
which directly bind to the JAK2 tyrosine kinase domain
and inhibit JAK tyrosine kinase activity (15). Overexpres-
sion of JAB and CIS3 resulted in the suppression of cyto-
kine signaling by using JAKs, including IL-6 and LIF (16).
Two other groups have reported on related genes: one re-
ferred to JAB, CIS2, and CIS3 as suppressor of cytokine
signaling (SOCS)1, SOCS2, and SOCS3, respectively (17),
whereas the other referred to them as STAT-induced
STAT inhibitor (SSI)1, SSI2, and SSI3, respectively (18).
Gene disruption studies have demonstrated that JAB/
SOCS1/SSI1 and CIS3/SOCS3/SSI3 negatively regulate
IFN-
 
g
 
 signaling (19–22) and fetal liver hematopoiesis (23),
respectively. However, the physiological function of CIS3
in adult tissues remains to be determined, as CIS3 gene dis-
ruption was embryonically lethal (23). Many reports have
indicated that CIS3 is induced by various inflammatory and
antiinflammatory cytokines such as IL-6, IFN-
 
g
 
,
 
 and IL-10
and that it negatively regulates those cytokine actions as
well as STAT functions (12). However, these studies used
primary cultured cells or cell lines, and few of them focused
on the relationship between CIS3 and STATs in vivo. In
this report, we examined the expression of CIS3 in colitis
and its relationship to STAT3 activation using mouse coli-
tis models. First, we demonstrated that IL-6 plays a crucial
role in the development of DSS-induced colitis, suggesting
that STAT3 activation is involved in the perpetuation of
colitis. We found that CIS3 was induced as colitis devel-
oped, whereas a high level of CIS3 expression rather sup-
pressed STAT3 activation. Forced expression of a domi-
nant negative form of JAB/CIS3 in mice resulted in a more
severe colitis induced by DSS. Thus, it is highly possible
that expression of CIS3 negatively regulates the pathogene-
sis of inflammation by modulating STAT3 activity.
 
Materials and Methods
 
Cells.
 
The human colon carcinoma cell line, HCT, and the
murine intestinal-derived epithelial cell line, CMT-93, were cul-
tured in DMEM containing 10% FCS (24). CMT-93 cells were
obtained from American Type Culture Collection (no. CCL
223). NIH-3T3 and 293 cells were cultured in DMEM contain-
ing 10% calf serum (CS). Human and mouse hematopoietic cell
lines (Raji, HEL, Ba/F3, and 32D) were cultured in RPMI con-
taining 10% FCS, as described (16).
 
Mice.
 
7–8-wk-old female BALB/c, C57BL6 mice were pur-
chased from SLC Co., Ltd., and the TCR-
 
a
 
 chain (TCR-
 
a
 
2
 
/
 
2
 
mice) were obtained from Charles River Laboratories. IL-6
 
2
 
/
 
2
 
,
IL-10
 
2
 
/
 
2
 
, and IFN-
 
g
 
2
 
/
 
2
 
 mice in a C57BL6 background were
obtained from The Jackson Laboratory. Mice with a cell type–
specific disruption of the STAT3 gene in macrophages and neu-
trophils (M
 
f
 
-STAT3
 
2
 
/
 
2
 
) have been described previously (25).
To create transgenic (Tg) mice, a pCAGGS-F59D-JAB expres-
sion vector was constructed by subcloning the F59D-JAB cDNA
(15) into the EcoRI cloning site of the pCAGGS as described
(14). After digestion with SalI and HindIII, the fragment-
containing promoter, F59D-JAB cDNA as well as the 3
 
9
 
 non-
coding region was used for microinjection into zygotes of
C57BL6XC3H (B6C3-F1) parents. Eggs surviving microinjec-
tion were transferred into the oviducts of recipient pseudo-preg-
nant females as described (14). Tg mice were identified by PCR
analysis of tail genomic DNA, and expression was confirmed by
reverse transcription (RT)-PCR using primer sets (GAT-
CCCATCGAATTCGAGTAG and GTGATGCGCCGGTAA-
TCGGA). Four independent lines were established and
B6C3XC57BL6-F2 mice were used for experiments. All animal
studies were approved by the institutional review board for ani-
mal experiments of Kurume University.
 
Patients and Samples.
 
Mucosal samples were taken from
freshly obtained intestinal resection specimens of patients with ul-
cerative colitis (UC) whose disease had been classified as active by
endoscopic and histopathological analyses. Mucosal samples were
also taken from involved areas of CD patients. The disease was
active in patients, as defined by a CD activity index (CDAI) of
 
.
 
150. In these patients, the primary site of involvement was ile-
ocolonic. In all four patients, indication for surgery was a chronic
active course poorly responsive to corticosteroid treatment or
other medical treatment. Biopsy samples were obtained from the
diseased colonic mucosa of a patient with infectious colitis (IC)
during colonoscopy. Microscopically unaffected areas of colon
cancer specimens were used as normal control colon. The collec-
tion of surgical samples was approved by the ethical committee
and the institutional review board of Kurume University.
 
DSS-induced Colitis.
 
Colitis was induced by means of drink-
ing water supplemented with 2–4% DSS (mol wt, 40,000; ICN
Biomedicals) as described previously (26). Control mice were
treated in a similar manner with drinking water without DSS.
The DAI and histological score were assessed in accordance with
established criteria (27), which combined scores of weight loss,
consistency, and bleeding divided by 3, and acute clinical symp-
toms with diarrhea and/or extremely bloody stools. Colonic sec-
tions were stained with hematoxylin and eosin and used for histo-
logical analysis. IL-6 and IL-10 levels were measured by ELISA
assay kits (Endogen) using the colon organ culture of DSS-treated
mice as described (28).
 
Antigen-induced and T Cell–induced Colitis.
 
The 2,4, 6-trini-
trobenzene sulfonic acid (TNBS)-induced colitis has been de-
scribed elsewhere (29). In brief, 1 wk before the induction of
colitis, mice were immunized with 1 mg of TNBS (Sigma- 
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Aldrich) in saline by intrarectal administration. Colitis was in-
duced by twice intrarectal administration of 0.5 mg TNBS in
50% ethanol at days 0 and 7. Mice were killed on day 14.
Induction of colitis by transfer of CD4
 
1 
 
T cells into SCID
mice was done as described previously (7). CD62L
 
1
 
CD4
 
1
 
 T cells
were isolated from normal Balb/c mice spleen by using anti-
CD62L and anti-CD4 monoclonal antibodies and magnetic
beads. Purified CD62L
 
1
 
CD4
 
1
 
 T cells expressed high levels of
CD45RB antigen. CD62L
 
1
 
CD4
 
1
 
 splenic T cells (10
 
6
 
) were in-
jected intravenously into C.B-17 SCID mutant mice. Mice were
killed on day 21.
 
Immunoblot Analysis.
 
Colon and other tissues obtained from
mice treated with DSS were immediately frozen in liquid nitro-
gen and stored at 
 
2
 
80
 
8
 
C. The whole colon of mice and intestinal
resection specimens of human patients were homogenized in 2–4
ml of a lysis buffer containing 50 mM Tris-HCl (pH 8.0)-0.5%
NP-40, 1 mM EDTA, 150 mM NaCl, 10% glycerol, 1 mM so-
dium vanadate, 50 mM sodium fluoride, 10 mM sodium pyro-
phosphate, and 1 mM phenylmethylsulfonyl fluoride with a pro-
tease inhibitor cocktail (Sigma-Aldrich; reference 14). The
extracts were cleared by spinning at 15,000 rpm at 4
 
8
 
 for 15 min
and then diluted with the lysis buffer to achieve 
 
z
 
2 mg/ml pro-
tein concentration. The total cell extracts were resolved by SDS-
PAGE, and proteins were detected by immunoblotting as de-
scribed (14, 23, 30). Anti-STAT1 (E-23), anti-STAT3 (C-20),
anti-STAT5 (C17), and anti-STAT6 (M-20) were purchased
from Santa Cruz Biotechnology, Inc. Tyrosine phosphorylation
of STATs was detected by using anti–phospho-STAT–specific
antibodies (anti-PY-STATs; New England BioLabs, Inc./Upstate
Biotechnology) as described (31). Rabbit polyclonal and mouse
monoclonal anti-CIS3 antibodies against COOH-terminal pep-
tide (204–225) have been described previously (23, 30) and were
obtained from Immuno-Biological Laboratories Co., Ltd.
 
Immunohistochemistry.
 
Colon tissues were fixed with 10% for-
malin, paraffin embedded, and sectioned. Slides were incubated
with either a 1:100 dilution of anti–phospho-STAT3–specific an-
tibodies (1:1 mixture of anti-PS-STAT3 and anti-PY-STAT3;
New England BioLabs, Inc.) or a 1:100 dilution of polyclonal
anti-JAB/SOCS1 (Immuno-Biological Laboratories) and stained
with LSAB kit according to the manufacturer’s instructions
(Dako). The samples were then lightly stained with hematoxylin
and examined.
 
Northern Hybridization.
 
Total RNA from various kinds of tis-
sue was prepared with Trizol (GIBCO BRL) according to the
manufacturer’s instructions. Total RNA (5 
 
m
 
g) was separated on
1.0% agarose gels containing 2.4% formaldehyde and then trans-
ferred to positively charged nylon membranes. After fixation un-
der calibrated ultraviolet irradiation, the membranes were hybrid-
ized with digoxigenin (DIG)-labeled riboprobes and visualized
using alkaline phosphatase–labeled anti-DIG antibody according
to the manufacturer’s instructions (Boehringer). The probe
cDNA for CIS3, JAB, and G3PDH has been described previously
(31).
 
In Situ Hybridization.
 
A PstI fragment of mouse CIS3 cDNA
was cloned into Bluescript (Stratagene). DIG-labeled sense and
antisense riboprobes were synthesized by using a DIG-RNA la-
beling kit (Boehringer) according to the manufacturer’s instruc-
tions. Colon tissue obtained from Balb/c mice treated with 4%
DSS for 7 d was cryostat sectioned to 7-
 
m
 
m thickness. Fixation in
4% formaldehyde, hybridization, and detection with DIG-labeled
probe were performed according to Boehringer’s protocol.
 
RT-PCR.
 
IL1
 
b
 
 and control G3PDH mRNAs were detected
by standard RT-PCR methods using Standard GeneAmp RNA
 
PCR kit (PE Biosystems) according to the manufacturer’s in-
structions. Primer sets were CAGAGTTCCCCAACTGGTA-
CAT and AAGGAGGAAACACAGGCTCTCT (IL-1
 
b
 
) and
ACCACAGTCCATGCCATCAC and TCCACCACCCTGT-
TGCTGTA (G3PDH).
 
Luciferase Assay.
 
The STAT3 responsive promoter-luciferase
reporter gene and LIF-dependent luciferase assay in 293 cells
transfected with Myc-tagged wild-type (WT) or mutant JAB
cDNA have been described (12).
 
Results
 
STAT3 Is Activated in Colitis.
 
First, we examined
which STAT is activated in colitis. Substantial amounts of
STAT1, STAT3, STAT5, and STAT6 were detected in
the colon of human UC and CD patients as well as DSS-
treated mice. DSS-induced colitis is an experimental acute
inflammatory bowel disease that is not dependent on T or
B cells, as it occurs in SCID mice that lack lymphocytes
(28). However, inflammatory cytokine production by mac-
rophages and/or epithelial cells has been shown to contrib-
ute to the pathophysiology of colitis (5). Among STAT1,
STAT3, STAT5, and STAT6, we could repeatedly detect
the phosphorylation of STAT3 in the colon of DSS-treated
mice as well as UC and CD patients (Fig. 1 A; PY-STAT),
whereas the phosphorylation of STAT1, STAT5, or
STAT6 was undetectable or very low by our assay. We also
examined STAT3 activation in other types of intestinal in-
flammation. STAT3 phosphorylation was evident in a non-
inflammatory bowel disease (IBD) infectious colitis patient
(Fig. 1 B, lane 1). STAT3 activation was also detected in
both Th1-dependent colitis in IL-10
 
2
 
/
 
2
 
 mice (Fig. 1 B,
lines 5 and 6) and macrophage- and neutrophil-specific
STAT3 conditional knockout (M
 
f
 
-STAT3
 
2
 
/
 
2
 
) mice (ref-
erence 25; lines 7 and 8) as well as in IL-4–dependent coli-
tis in TCR-
 
a
 
 chain knockout (TCR
 
2
 
/
 
2
 
) mice (reference
32; lane 9). STAT3 activation was also observed in other T
cell–dependent colitis induced by the haptenating reagent,
TNBS (lanes 11 and 12) as well as by transplantation of
CD45RB
 
high
 
CD4
 
1 
 
T cells into SCID mice (line 13). Thus,
STAT3 was activated not only in acute T cell–independent
colitis but also in chronic T cell–dependent colitis. Clinical
signs such as persistent diarrhea and the macroscopic exam-
ination of colon tissues indicated that the IL-10
 
2
 
/
 
2
 
 mice
suffered from much more severe colitis than the M
 
f
 
-
STAT3
 
2
 
/
 
2
 
 mice, probably due to the difference of age (IL-
10
 
2
 
/
 
2
 
 mice were 16 wk old, whereas M
 
f
 
-STAT3
 
2
 
/
 
2
 
 mice
were 9 wk old). Higher levels of STAT3 phosphorylation
were observed in the IL-10
 
2
 
/
 
2
 
 mice than in the M
 
f
 
-
STAT3
 
2
 
/
 
2
 
 mice (cf. lanes 5 and 6 and lanes 7 and 8). Fur-
thermore, in the TNBS-induced colitis, one of the two
mice (TNBS-1) showed much more severe symptoms
along with stronger STAT3 phosphorylation than those of
the other (TNBS-2; cf. lanes 11 and 12). The severity of
colitis in the CD4
 
1 
 
T cell–transplanted SCID mouse was
rather mild compared with other colitis that we examined
in this study, and STAT3 phosphorylation in the colon was
weak (lane 13). These data suggest that the levels of 
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STAT3 phosphorylation were well correlated to the sever-
ity of colitis.
We examined in which cell types STAT3 was being ac-
tivated by using immunohistochemistry with anti–phos-
pho-STAT3–specific antibodies (Fig. 1 C). Nuclear accu-
mulation of activated STAT3 was observed in epithelial
cells
 
 
 
as well as lamina propria cells in DSS-induced mouse
colitis but not in untreated colon, indicating that STAT3 is
activated not only in infiltrated cells but also in epithelial
cells in colitis.
STAT3 has been shown to be mainly activated by IL-6–
related cytokines, and the elevation of the IL-6 level has
been reported in DSS-induced colitis. On the other hand,
IFN-
 
g
 
 has been shown to activate mainly STAT1. For this
reason, we investigated the role of STAT3 in the pathology
of DSS-induced colitis using IL-6
 
2
 
/
 
2
 
 and IFN-
 
g
 
2
 
/
 
2
 
 mice
in a C57BL/6 background (Fig. 2). All IL-6
 
1
 
/
 
1
 
 mice de-
veloped severe colitis characterized by loss of weight,
marked epithelial hyperplasia, extensive leukocyte infiltra-
tion, and goblet cell depletion. Inflammatory infiltrates,
which consisted mainly of mononuclear cells, were ob-
served in the lamina propria in WT mice. These changes
were not very obvious in IL-6
 
2
 
/
 
2
 
 mice (Fig. 2, A and B).
On the other hand, IFN-
 
g
 
–deficient mice developed coli-
tis as severely as WT mice. Then, we compared STAT3
activation in WT and IL-6
 
2
 
/
 
2
 
 mice. As shown in Fig. 2 C,
STAT3 phosphorylation in the colon of WT mice was
much more intensive than that in IL-6
 
2
 
/
 
2
 
 mice. These data
suggest that STAT3 activation in intestinal cells contributes
to the development of colitis and constitutive activation of
STAT3 may prevent healing of colitis.
Correlation between CIS3 Induction and STAT3 Activation
in Colitis. As CIS3/SOCS-3 and JAB/SOCS-1 have
been suggested to be involved in the negative regulation of
inflammatory cytokine signaling, including IL-6 and IFN-g,
we investigated how CIS3 and JAB are implicated in coli-
tis. We did not observe a drastic increase in JAB message in
DSS-induced colitis (see Fig. 4) or human colitis patients
(data not shown). Total RNA was isolated from colon
samples, and CIS3 mRNA expression was detected using
Northern hybridization (Fig. 3 A). An elevated CIS3
mRNA level was observed in the colon of Balb/c mice
treated with 4% DSS for 7 d (lane 4). CIS3 expression was
also elevated in the colon of TCR2/2 mice (lane 6) com-
pared with that of WT syngenic mice (lane 5). Elevated ex-
pression of CIS3 was also observed in all of the chronic
colitis models described in Fig. 1 B including IL-102/2
mice (lines 9 and 10), Mf-STAT32/2 mice (lines 11 and
Figure 1. Expression and activation of STATs in
human and mouse colon tissues. (A) Colon tissue
extracts from the normal region (NR) of colon
cancer patients (lane 1), those from UC or CD pa-
tients (lanes 2–4), or those from Balb/c mice
treated without (day 0) or with 4% DSS for 7 d
(lanes 5 and 6) were immunoblotted with antiphos-
pho-STATs (PY-STAT) or anti-STAT antibodies.
As a positive control (pos), IFN-g–treated NIH-
3T3 cells (for STAT1), LIF-treated CMT cells
(STAT3), IL-3–treated Ba/F3 cells (STAT5), and
IL-4–treated 32D cells (STAT6) are shown in lane
7. We analyzed more than seven patients and three
DSS-treated mice, obtaining similar results. (B)
STAT3 activation in UC and IC patients (lanes 1
and 2) as well as several mouse models (lanes 3–13).
Colon samples were obtained from 10–15-wk-old
WT C57BL6 mice (lanes 3 and 4), 16-wk-old IL-
102/2 mice (lanes 5 and 6), 9-wk-old Mf-
STAT32/2 mice (lanes 7 and 8), 15-wk-old
TCR2/2 mouse (lane 9), TNBS-treated (lanes 11
and 12) or untreated (lane 10) mice, and CD41 T
cell–transplanted SCID mouse (lane 13). (C) Im-
munohistochemical detection of activated STAT3
in DSS-induced colitis. C57BL6 mice were treated
with (b and d) or without (a and c) 2% DSS for 5 d,
and colon tissues were fixed with 10% formalin.
Slides with sectioned tissues of 7-mm thickness
were immunostained with anti–phospho-STAT3–
specific antibodies (c and d) or control IgG (a and
b) and were lightly stained with hematoxylin.475 Suzuki et al.
12), TNBS-induced colitis (lanes 13 and 14), and
CD45RBhighCD41  T cell–mediated colitis (lane 15). Inter-
estingly, the expression levels of CIS3 mRNA were not di-
rectly correlated to the extent of STAT3 phosphorylation
in these model mice (cf. Fig. 1 B). CIS3 levels in Mf-
STAT32/2 mice were higher than those in IL-102/2 mice
(cf. Fig. 3 A, lanes 9 and 10 and 11 and 12), whereas
STAT3 phosphorylation in IL102/2 mice was stronger
than that in Mf-STAT32/2 mice (Fig. 1 B, lanes 5 and 6
and 7 and 8). Furthermore, TNBS-2 mouse (Fig. 3 A, lane
14) exhibited higher level of CIS3 expression but lower
level of STAT3 activation (Fig. 1 B, lane 12) compared
with the TNBS-1 (Fig. 1 B, lane 11, and Fig. 3 A, lane 13).
These data suggest that STAT3 activation and CIS3 induc-
tion are strongly correlated, but these are not simple paral-
lel events.
We also examined CIS3 levels in colon samples from
UC, CD, and IC patients. In these cases, CIS3 expression
was higher than normal in the colon samples (Fig. 3 A,
lanes 18–23; representative data from seven patients are
shown). As shown in Fig. 3 B, the expression of CIS3 in
protein level was confirmed by immunoblotting with anti-
CIS3 monoclonal antibody. CIS3 protein was induced by
treatment with LIF in HCT, a human colon carcinoma cell
line (lanes 1 and 2). A high level of CIS3 protein was de-
tected in the colon of DSS-treated mice (lane 4) as well as
in a UC patient (lane 6), but not in normal colons (lanes 3
and 5).
To determine which cells express CIS3, we performed
in situ hybridization in a DSS-treated colon (Fig. 3 C).
CIS3 mRNA was mainly detected in hyperplastic epithelial
cells and lamina propria cells (Fig. 3 C, panels b and d) but
also weakly in lymphoid cells (Fig. 3 C, panel b). Sense oli-
gonucleotides did not hybridize at all (Fig. 3 C, panel a).
CIS3 expression was not very obvious in a normal colon
(Fig. 3 C, panel c). These data suggested that STAT3 phos-
phorylation and CIS3 expression occurred at the same re-
gion of DSS-induced colitis.
Time Course of STAT3 Activation and CIS3 Induction in
DSS-induced Colitis. We postulated that CIS3 is involved
in the pathological deterioration of colitis. To explore this
possibility further, we examined the time course of STAT3
activation and CIS3 expression in DSS-induced colitis. The
colon inflammation became severe at day 7, and mice re-
covered from colitis on day 14, after DSS had been re-
moved from the drinking water at day 8 (Fig. 4 A). As
shown in Fig. 4 B, STAT3 phosphorylation was transiently
observed in DSS-treated mice, reached a plateau on days
3–5, and decreased thereafter. JAB was not induced very
intensively compared with CIS3 (Fig. 4 B, Northern). On
the other hand, CIS3 mRNA levels reached a plateau on
day 7 and maintained a high level until day 10, gradually
decreasing thereafter as mice recovered from their severe
pathological condition. CIS3 mRNA was not elevated in
DSS-treated IL-62/2 mice (data not shown), suggesting
that CIS3 expression is regulated by the IL-6/STAT3 sys-
tem. This is consistent with our previous observation that
CIS3 is induced by IL-6 via STAT3 in hematopoietic cells
(31). These data suggest that STAT3 is activated as a result
of an increase in the IL-6 level and that the CIS3 level in-
Figure 2. DSS-induced colitis in
IL-62/2 and IFN-g2/2 mice. (A)
Time course of body weight loss.
WT C57BL6 mice or IL-62/2 or
IFN-g2/2 mice (n 5 3 for each
knockout mice) were treated with
2% DSS for indicated periods, and
body weight was measured daily.
Relative body weight (%) com-
pared with that of day 0 is plotted
with a standard error. Results were
analyzed using the t test. A P value
of ,0.05 was considered to be sta-
tistically significant. (B) Histologi-
cal section of an ulcer with hema-
toxylin and eosin staining.
Pathology was graded on a scale of
0–12. Data represent the average
with SEM for the group. The av-
erage score for IL-62/2 mice, but
not IFN-g2/2 mice, was signifi-
cantly different from that for the
WT mice (P 5 0.013). Statistical
analysis was performed using the t
test. (C) STAT3 phosphorylation
in the colon of WT and IL-62/2
mice treated with DSS. Colon tissue
extracts from three independent
mice of each strain were immuno-
blotted with anti–phospho-STAT3
(aPY-STAT3) and anti-STAT3
(aSTAT3) antibodies.476 Negative Regulation of STAT3 and Colitis by CIS3/SOCS3
creases thereafter. Subsequently, CIS3 may reduce the se-
verity of colitis through the suppression of STAT3 activa-
tion.
We confirmed the induction of CIS3 in colon epithelial
cells and the effect of forced expression of CIS3 on STAT3
activity using a cultured intestinal epithelial cell line,
CMT-93 (24). As shown in Fig. 5 A, STAT3 activation is
also ahead of CIS3 induction in CMT cells, and the level of
CIS3 was maintained even after STAT3 phosphorylation
disappeared. It has been demonstrated that expression of
the proinflammatory cytokine IL-1b is regulated by STATs
(33). As shown in Fig. 5, B and C, forced expression of
CIS3 suppressed LIF-induced STAT3 phosphorylation as
well as IL-1b production. These data suggest that CIS3 is
induced via STAT3 and that CIS3 suppresses STAT3 acti-
vation in a colon-derived cell line. Repression of STAT3
activity by CIS3 in epithelial cells may contribute to sup-
pression of the severity of colitis by reducing proinflamma-
tory cytokine production.
A Mutant Form of JAB/SOCS1 Reversed the Negative Effect
of JAB and CIS3 and Induced More Severe Colitis in Tg
Mice. To investigate the physiological meaning of STAT3
activation and CIS3 expression more precisely in DSS-
induced colitis, we developed a dominant negative form of
CIS3 and JAB. We have previously shown that both JAB
and CIS3 possess two JAK binding sites, kinase inhibitory
region (KIR), and an SH2 domain (15). We found that a
point mutation either in KIR or the SH2 domain (F59D-
JAB or R105E-JAB) strongly augmented LIF-induced
STAT3 activation (data not shown). We examined the ef-
fect of F59D-JAB on JAB- and CIS3-mediated suppression
of STAT3 activation. As shown in Fig. 6, A and B, overex-
pression of F59D-JAB reverted the negative effect of both
Figure 3. Expression of CIS3 in colon tissue obtained from several colitis
model mice and human patients. (A; Northern) Mucosal samples were taken
from intestinal resection. Total RNA was extracted from NIH-3T3 cells
treated without (lane 1) or with 1,000 U/ml IFN-g for 30 min (lane 2), colon
tissue obtained from Balb/c mice without (lane 3) or with DSS-induced colitis
(lane 4) for 7 d, TCR2/2 mice (lane 6), or control syngenic mice (lane 5).
RNA samples were also obtained from colon tissues from the same mice de-
scribed in the legend to Fig. 1; WT C57BL6 mice (lanes 7 and 8), IL-102/2
mice (lanes 9 and 10), Mf-STAT32/2 mice (lanes 11 and 12), TNBS-treated
(lanes 13 and 14), and CD41 T cell–transplanted SCID mice (lane 15). Total
RNA was also extracted from human mucosal samples taken from intestinal re-
sections from non-IBD control patients (lanes 16 and 17), or UC (lanes 18 and
19), CD (lanes 21 and 22), or IC (lane 23) patients. The human cell lines Raji
(lane 24) and HEL (lane 25) were used as negative and positive controls for
CIS3 mRNA, respectively. Northern hybridization was performed with
cDNA probes for coding regions of human and murine CIS3 and control
G3PDH. We analyzed more than nine UC or CD patients and obtained similar
results. Representative data are shown. (B; Western) Expression of CIS3 pro-
tein in colitis. Cell extracts were prepared from HCT cells treated without
(lane 1) or with (lane 2) 2 ng/ml LIF for 3 h, colon tissues of Balb/c mice
treated without (lane 3) or with (lane 4) 4% DSS for 7 d, or colon tissues from
non-IBD control (lane 5) or UC patients (lane 6). CIS3 protein was immunoprecipitated with a rabbit anti-CIS3 polyclonal antibody and then immuno-
blotted with a mouse anti-CIS3 monoclonal antibody. (C) Localization of CIS3 expression examined by in situ hybridization. Balb/c mice were treated
with 4% DSS in the drinking water for 7 d. Colon tissues from DSS-treated (a, b, and d) or untreated (c) mice were cryostat sectioned to 7-mm thickness.
After fixation of samples with 4% formaldehyde, hybridization and detection were performed with DIG-labeled CIS3 antisense (b–d) and sense (a)
probes. The samples were lightly stained with 1% methyl green. Original magnification: 320 (a and b), 340 (c), and 3100 (d).
Figure 4. Time course of
DSS-induced body weight loss
(A), STAT3 activation, and in-
duction of CIS3 and JAB (B) in
mouse colon after DSS treat-
ment. Balb/c mice were treated
with 4% DSS for indicated peri-
ods. (A) Mice (n 5 3 for each
DSS concentration) were treated
with indicated concentrations of
DSS, and body weight was mea-
sured daily. The relative body
weight (%) compared with that
of day 0 is plotted with a stan-
dard error. (B, Western) Colon
tissue extracts from mice treated
with DSS for indicated periods
were immunoblotted with anti–
phospho-STAT3 (aPY-STAT3)
and anti-STAT3 (aSTAT3) antibodies. (B, Northern) Total RNA was
extracted from the colon. Northern hybridization using cDNA probes for
mouse CIS3, JAB, and control G3PDH was performed.477 Suzuki et al.
WT JAB and CIS3 on LIF-induced STAT3 reporter gene
activation (Fig. 6 A) as well as STAT3 phosphorylation
(Fig. 6 B) in 293 cells. Although the precise molecular
mechanism is under investigation and will be published
elsewhere, we speculate that F59D-JAB masks the phos-
phorylated activation loop of JAKs, thereby preventing the
binding of JAB or CIS3 to the catalytic pocket of the JAK
tyrosine kinase domain.
To examine the effect of F59D-JAB expression in DSS-
induced colitis, we created four F59D-JAB Tg mice using a
b-actin promoter (14). Expression was observed in most
tissues except for liver and brain in a typical Tg line (Fig. 7
A). In the colon, F59D-JAB protein was expressed in most
cells including goblet, epithelial, and lamina propria cells
(Fig. 7 B). As shown in Fig. 8 A, Tg lines exhibited stron-
ger STAT3 activation in the colon of DSS-treated mice
than in that of their WT littermates. Our WT littermates
were slightly resistant against DSS-induced colitis com-
pared with C57BL/6 mice. As shown in Fig. 8, B and C,
all F59D-JAB Tg mice exhibited a more extensive loss of
weight (Fig. 8 B) and a more severe epithelial hyperplasia
and goblet cell depletion than their WT littermates (Fig. 8
C) when they received appropriate concentrations of DSS
in water. These data suggest that expression of F59D-JAB
resulted in hyperactivation of STAT3 and a more severe
pathological profile in DSS-induced colitis.
Next, we measured IL-6 and IL-10 levels in colon organ
culture from WT and Tg mice. As shown in Fig. 9, IL-6
and IL-10 levels were not significantly different, suggesting
that the more severe colitis in Tg mice was not due to
higher levels of IL-6 or lower levels of IL-10. Taken to-
gether, our data suggest that sustained activation of STAT3
perpetuated the development of DSS-induced colitis and
that CIS3 induction by STAT3 may play an important role
in STAT3 repression and in the termination or healing of
colitis.
Discussion
In this study, we focused on the role of STAT3 activa-
tion and CIS3/SOCS3 expression in colitis using model
mice. STAT3 activation was found in almost all colitis
models examined in this study including DSS treatment,
TCR-a gene knockout, CD41 T cell transfer, IL-10
knockout, macrophage- and neutrophil-specific STAT3
conditional knockout, as well as TNBS immunization.
Conditional knockout of STAT3 in macrophages and neu-
trophils resulted in chronic enterocolitis with age (25). This
is probably due to the enhancement of the Th1 response by
the block of antiinflammatory cytokine IL-10 signaling.
Colitis in TCR-a knockout is IL-4 dependent (32) and
both Th1- and Th2-type cytokines are involved in the de-
velopment of distinct forms of TNBS-induced colitis (29).
Therefore, STAT3 is activated in many type of colitis irre-
spective of the cause, suggesting that STAT3 activation is
Figure 6. The effect of F59D-JAB on STAT3 repression by WT JAB
and CIS3 in 293 cells. (A) 293 cells were transfected with 10 ng WT JAB
or CIS3, APRE-luciferase reporter gene, and indicated amounts of
F59D-JAB plasmid (ng). 2 d after transfection, LIF-induced STAT3 acti-
vation was measured by luciferase assay. (B) 293 cells were transfected
with 100 ng Myc-tagged WT JAB or CIS3 and hemagglutinin (HA)-
tagged STAT3 with indicated amounts of F59D-JAB. After stimulation
with 100 ng/ml LIF for 30 min, cell extracts were immunoprecipitated with
anti-HA, and then the immunoprecipitates (aHA-IP) were blotted with
anti-phosphorylated STAT3 (aPY-STAT3) or anti-STAT3 (aSTAT3).
Total cell extracts (TCL) were blotted with anti-Myc (aMyc) and anti-
JAB (aJAB) antibodies to confirm the expression of Myc-JAB, Myc-
CIS3, and F59D-JAB.
Figure 5. Activation of STAT3, induction of CIS3 protein, and the ef-
fect of forced expression of CIS3 on LIF-induced STAT3 activation and
IL-1b production in a mouse colon cell line, CMT. (A, Western) Cells
grown in six-well dishes were stimulated with 10 ng/ml LIF for indicated
periods, and total cell extracts were then immunoblotted with anti–phos-
pho-STAT3, anti-STAT3, and rabbit anti-CIS3 polyclonal antibodies. In
B and C, CMT cells stably transformed with CIS3 (CMT-CIS3) were
stimulated with 10 ng/ml LIF for indicated periods, and then STAT3
phosphorylation and IL-1b production were measured by immunoblot-
ting (B, Western) and RT-PCR analysis (C, RT-PCR), respectively.
Three independent CMT transformants were examined and similar re-
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related to the progression or development of the disease
rather than the initiation. We frequently observed that the
levels of STAT3 phosphorylation correlated to the severity
of colitis, which supports this hypothesis. Therefore,
STAT3 activation may more likely be involved in the pro-
cess of controlled inflammation rather than colitis itself.
As IL-6 is a major activator of STAT3 in inflammation,
and overproduction of IL-6 has been found in many type
of colitis, IL-6 may play an important role in the develop-
ment of colitis. Recently, Yamamoto et al. (6) and Atreya
et al. (7) reported that administration of anti–IL-6 receptor
monoclonal antibodies suppressed colitis induced by trans-
plantation of CD45RBhighCD41 T cells into SCID mice.
These studies demonstrated that IL-6 perpetuates colitis by
protecting lamina propria T cells from apoptosis. We also
showed that IL-6–deficient mice developed less severe
colitis induced by DSS, suggesting that IL-6 also play a
promotive role in T cell–independent, acute colitis. Al-
though IL-6 also activates the Ras–mitogen-activated pro-
tein (MAP) kinase pathway, phosphorylation of MAP ki-
nase (Erk2) was not often observed in DSS-induced colitis.
Therefore, we focused on STAT3 activation in IL-6 signal-
ing in colitis. The mechanism whereby IL-6/STAT3 in-
creases the severity of colitis is not clear at present. It has
been suggested that IL-6 protects the apoptosis of CD41 T
cells in developing colitis (6, 7), leading to the deterioration
of the pathological condition. This may also be possible in
epithelial cells, resulting in the hyperproliferation of both
epithelial and lamina propria cells in response to IL-6. IL-
6–activated macrophages and colon epithelial cells have
Figure 8. DSS-induced STAT3 activation and colitis in F59D-JAB Tg mice. (A, panels a and b; West-
ern) colon tissue extracts from two lines of WT littermate or Tg mice treated with 2% DSS for 7 d mice
were immunoblotted with anti–phospho-STAT3 (aPY-STAT3) and anti-STAT3 (aSTAT3) antibodies.
(A, panels c and d; RT-PCR) F59D-JAB expression in the colon sample was confirmed by RT-PCR anal-
ysis. Results from two representative independent Tg lines (line 27 and line 46) are shown. (B) Time course of DSS-induced body weight loss. WT lit-
termates or F59D-JAB Tg mice were treated with 2% DSS for indicated periods, and body weight was measured daily. We examined four independent
Tg lines (total n 5 10). Relative body weight (%) compared with that of day 0 is plotted with a standard error. Results were analyzed using the t test. A
P value of ,0.05 was considered to be statistically significant. (C) Histological section of an ulcer with hematoxylin and eosin staining. Pathology was
graded on a scale of 0–12. Data represent the average with SEM for the group.
Figure 7. Expression of F59D-JAB in Tg mice. (A) RT-PCR analysis for tissues from F59D-JAB Tg mouse. 1 mg total RNA from each tissue was
used as a template to detect F59D-JAB and control G3PDH mRNAs. Similar levels of expression were observed in the other three Tg lines. (B) Immu-
nohistochemical detection of F59D-JAB in the colon of WT littermate or F59D-JAB Tg mouse (Tg).479 Suzuki et al.
been shown to secrete inflammatory cytokines, including
TNF-a and IL-1b, which contribute to the development
of colitis. These cytokines activate nuclear factor (NF)-kB
pathway. TNF-a has been shown to play an important role
in the development of inflammation, including colitis (2,5).
However, as IL-62/2 mice developed less severe DSS-
induced colitis as well as antigen- or collagen-induced ar-
thritis (8–10), STAT3 pathway is also important for inflam-
mation. Further study is necessary to clarify the relationship
between TNF-a/NF-kB and IL-6/STAT3 pathways.
STAT3 probably plays both positive and negative roles
in the development of inflammation. To assess the role of
STAT3 in vivo more precisely, the STAT3 gene was dis-
rupted in a tissue- or cell-specific manner by the Cre-loxP
recombination system. In STAT3-deficient T cells, IL-6–
induced T cell proliferation was impaired due to the lack of
IL-6–mediated prevention of apoptosis (34), which is con-
sistent with the protective effect of anti–IL-6 receptor
monoclonal antibody against T cell–mediated colitis (6, 7).
Suppression of epithelial apoptosis and delayed mammary
gland involution was observed in mice with a conditional
knockout of STAT3 in the mammary gland (35). Thus,
hyperactivation of STAT3 may induce apoptosis of epithe-
lial cells in certain conditions. These data suggest that
STAT3 plays a different, sometimes opposite, role in the
apoptosis, proliferation, and cell functions of different cell
types. However, as DSS-induced colitis is, at least, T cell
independent, STAT3 activation may have a prominent role
to promote inflammation by enhancing inflammatory cy-
tokine production from epithelial cells or inducing prolifer-
ation of epithelial cells in DSS-treated mice. Therefore,
suppression of STAT3 activity may be necessary for the
elimination of inflammation in the colon.
We found that CIS3 was highly expressed in epithelial
and lamina propria cells in the colon of DSS-treated mice
but not in normal mice. A high level of expression of CIS3
was also observed in human UC and CD as well as in
TCR-deficient mice. These data suggest that CIS3 expres-
sion is observed not only in acute colitis but also in other
kinds of chronic colitis in which activated T cells are in-
volved. However, STAT3 activation and CIS3 expression
were not simply parallel events. A time course experiment
indicated that STAT3 activation was 1 d ahead of CIS3 in-
duction; STAT3 activation became apparent during days 3–5
and decreased thereafter, whereas CIS3 expression was in-
duced at day 5 and maintained high levels thereafter. Based
on the evidence that forced expression of CIS3 can inhibit
IL-6–mediated STAT3 activation, CIS3, which is induced
by STAT3 activation, acts as a negative feedback regulator
of STAT3. The negative effect of CIS3 on STAT3 activa-
tion in colon epithelial cells is confirmed by the forced ex-
pression of CIS3 in CMT-93 cells (Fig. 5). These data raise
the possibility that CIS3 expression is one, if not the only
one, mechanism that negatively regulates inflammatory re-
action in colitis. This is consistent with our observation in
F59D-JAB Tg mice, which exhibited a severe inflamma-
tory reaction along with the hyperactivation of STAT3.
Induction of CIS3 may terminate further activation of
STAT3, which contributes to the healing of colitis.
However, we observed both strong activation of STAT3
and high level of CIS3 in CD and UC patients. This may
be explained by the possibility that the CIS3 expression in
chronic symptoms may not reach a high enough level to
shut off STAT3 activation completely because of an ex-
tremely high IL-6 level in chronic patients. Alternatively,
CIS3 function may be suppressed by posttranslational mod-
ification or by the altered expression of interacting proteins.
CIS3/SOCS3 has been shown to be phosphorylated and
probably ubiquitinated in response to cytokine stimulation
(30, 36). These modifications and rapid degradation by
proteasome could be reasons for the incomplete suppres-
sion of STAT3 by CIS3 in chronic inflammation. As CIS3
is induced not only by IL-6 but also by many other cyto-
kines and growth factors, induction of CIS3 by antiinflam-
matory cytokines or growth factors may also be important
for the downregulation of STAT3 activation and lead to
the healing of colitis.
We found that an F59D-JAB mutant could overcome
the negative effect of WT CIS3 and JAB in cultured cells.
A detailed analysis of the mechanism of this “dominant
negative” effect is under way. This mutant will be a useful
tool to investigate the role of CIS3 and JAB in diseases.
Our F59D-JAB Tg mice grew normally and did not exhib-
ited any significant differences, from their WT littermates,
without stimulation. This is very different from JAB or
CIS3 knockout mice, which exhibit neonatal or embryonic
lethality, respectively. This discrepancy may be due to a
low level of expression of F59D-JAB in our Tg mice,
which can only partially overcome the negative effect of
JAB and CIS3. A high level of F59D-JAB expression may
be lethal in Tg mice, because we obtained no Tg pups
when we injected other tagged constructs that ensure a
higher level of F59D-JAB expression into zygotes. To con-
firm the role of CIS3 or JAB in intestinal inflammation, a
study of the conditional knockout of these genes is being
undertaken.
Figure 9. IL-6 and IL-10 pro-
duction in organ cultures from
colons of DSS-treated mice.
WT, F59D-JAB-Tg, or IL-62/2
mice were treated with 2% DSS
for 7 d, and cytokine levels were
measured by standard enzyme
immunoassay in 24-h organ cul-
ture of the distal region of the
colon samples (n 5 2).480 Negative Regulation of STAT3 and Colitis by CIS3/SOCS3
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